Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GND-03
- Development stage
- Preclinical
- Lead developer
- Gandeeva Therapeutics
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
GND-03 is a preclinical drug candidate being developed by Gandeeva Therapeutics for the treatment of various cancers. It is an "inhibitory" molecular glue (iGlue™), a type of small molecule designed to stabilize protein-protein interactions in a way that inhibits the function of a target protein. GND-03 was discovered using Gandeeva's proprietary platform that integrates artificial intelligence with cryogenic electron microscopy (cryo-EM) to visualize and target protein interfaces that were previously considered undruggable. As of early 2024, the specific molecular target of GND-03 remains undisclosed, and the program is in the discovery and optimization stage.
Beyond the preview
Go deeper on GND-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GND-03.